Q1 Earnings Forecast for RCKT Issued By William Blair

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Thursday, February 27th. William Blair analyst S. Corwin forecasts that the biotechnology company will earn ($0.27) per share for the quarter. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share. William Blair also issued estimates for Rocket Pharmaceuticals’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.25 EPS and FY2026 earnings at ($0.04) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06.

A number of other research analysts have also issued reports on the company. Needham & Company LLC lowered their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating on the stock in a report on Friday. The Goldman Sachs Group decreased their price objective on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a report on Monday. Scotiabank increased their target price on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday. Leerink Partners reduced their target price on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Finally, Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.30.

Rocket Pharmaceuticals Trading Down 7.0 %

Shares of RCKT stock opened at $8.79 on Monday. The stock has a fifty day moving average of $10.89 and a two-hundred day moving average of $14.66. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The firm has a market capitalization of $801.27 million, a PE ratio of -3.20 and a beta of 0.98. Rocket Pharmaceuticals has a 1 year low of $8.78 and a 1 year high of $30.94.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in Rocket Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 582 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Rocket Pharmaceuticals by 73.5% during the third quarter. Harbor Capital Advisors Inc. now owns 168,506 shares of the biotechnology company’s stock worth $3,112,000 after purchasing an additional 71,372 shares during the period. Privium Fund Management B.V. lifted its position in Rocket Pharmaceuticals by 17.5% during the third quarter. Privium Fund Management B.V. now owns 294,800 shares of the biotechnology company’s stock worth $5,445,000 after purchasing an additional 43,820 shares during the period. Pier 88 Investment Partners LLC boosted its holdings in shares of Rocket Pharmaceuticals by 5.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 32,490 shares of the biotechnology company’s stock valued at $600,000 after purchasing an additional 1,590 shares in the last quarter. Finally, First Turn Management LLC boosted its position in Rocket Pharmaceuticals by 10.8% in the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock valued at $11,476,000 after buying an additional 60,317 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.